Female patients more likely to survive but experience worse side effects from chemotherapy
An analysis of over 3000 patients with cancer of the oesophagus and stomach suggests female patients are more likely to survive longer than male patients, but experience more nausea, vomiting, and diarrhoea during therapy.
Senior author Professor David Cunningham OBE, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust said: “This is a significant finding based on a large scale data set, and furthers our understanding about two types of cancer that affect almost 16,000 people each year in the UK alone.”
“The complexity of cancer is a constant challenge to developing effective treatments, with hundreds of different types affecting patients in different ways. At The Royal Marsden, we are focused on developing smarter, kinder and more personalised treatments.”
Researchers are following on from this study by looking at tumour samples from patients enrolled into the trials to identify, at a molecular level, markers that may help to predict which patients do well and which don’t.
This study was funded by the Gastrointestinal and Lymphoma Research Unit at The Royal Marsden and the MRC CTU at UCL.